Evidence map›Paper›PMID 40649827›Full record

ArticleInternational journal of molecular sciences2025

Effects of High Glucose on Simulated Ischemia/Reperfusion Injury in Isolated Cardiomyocytes.

Miriam J K Walter, Masakazu Shiota, Zhu Li, Matthew B Barajas, Takuro Oyama, Matthias L Riess

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miriam J K WalterDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0009-0005-5918-3897
Masakazu ShiotaDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Zhu LiDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0001-6228-8845
Matthew B BarajasDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0002-3313-3112
Takuro OyamaDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0003-0627-6836
Matthias L RiessDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0001-8748-5757

Funding

BLRD VA I01 BX003482BLRD VA I01 BX005993NIH HHS Training in Perioperative Science Award [grant number 5T32 GM108554]Society of Cardiovascular Anesthesiologists Starter GrantVanderbilt University Medical Center Discretionary Funds
6 · The paper itself

Abstract

The rising prevalence of type 2 diabetes is linked to an increased risk of cardiovascular diseases, with the diabetic heart being particularly vulnerable to ischemia-reperfusion (IR) injury. Chronic hyperglycemia contributes to an increase in reactive oxygen species and impacts the homeostasis of biochemical pathways, including the polyol pathway, increasing susceptibility to damage. Aldose reductase (AR), a key enzyme in this pathway, has been targeted for therapeutic intervention, with AR inhibitors showing potential in mitigating diabetic complications. This study investigated IR injury in cardiomyocytes following high glucose exposure and assessed the AR inhibitor Epalrestat as a protective agent. Cardiomyocyte function was evaluated by measuring lactate dehydrogenase (LDH) release, FM1-43 membrane incorporation, cell viability, intracellular calcium accumulation, and superoxide anion formation. High glucose exposure and simulated IR led to increased LDH release, FM1-43 incorporation, intracellular calcium, and superoxide levels, alongside reduced cell viability in a dose-dependent manner. However, Epalrestat treatment during high glucose exposure significantly reduced IR-induced injury. These findings suggest that high glucose exacerbates IR injury in cardiomyocytes, with the polyol pathway playing a critical role. Targeting this pathway with AR inhibitors like Epalrestat may offer a protective strategy against diabetic heart complications.

Indexed as

GlucoseMyocardial Reperfusion InjuryMyocytes, CardiacAldehyde ReductaseAnimalsCalciumCells, CulturedCell SurvivalL-Lactate DehydrogenaseRatsReactive Oxygen SpeciesRhodanineSuperoxidesThiadiazolesThiazolidinesAldehyde ReductaseCalciumepalrestatGlucoseL-Lactate DehydrogenaseReactive Oxygen SpeciesRhodanineSuperoxidesThiadiazolesThiazolidinesaldose reductasecardioprotectiondiabetes mellitusdiabetic complicationshyperglycemiareactive oxygen species

Identifiers

PMID40649827
PMCPMC12250458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.